← Markets

Immatics N.V.

IMTX · NASDAQ

Market closed$9.59$0.190000 (+2.02%)After hours $9.59 · 0.00%

Key statistics

Previous close$9.40
Open$9.16
Day high$9.83
Day low$9.16
52-week high$12.41
52-week low$5.05
Market cap1.29B
Volume393.66K
Average volume477.20K
P/E ratio-4.82
Forward P/E—
EPS-1.99
Dividend yield0.00%

Market context

Why it moved

Immatics (IMTX) rose today after announcing three presentations of its PRAME-targeted pipeline data, including Phase 1 results from its IMA203CD8 cell therapy and IMA402 bispecific, at the prestigious ESMO Congress 2026, signaling continued clinical progress and boosting investor confidence.

StocktitanStocktitanInstagramInstagramStocktitan

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Immatics N.V. rose over 2% as the company announced three presentations at the ESMO 2026 Congress (Oct. 23–27, Madrid), showcasing clinical data across its PRAME-targeted franchise — including anzu-cel in metastatic melanoma, IMA203CD8 across solid tumors, and bispecific IMA402 at its recommended Phase 2 dose. The data readouts reinforce Immatics' positioning as a PRAME-focused leader spanning cell therapies and bispecifics, with analyst consensus bullish (median price target of $21.50, well above current levels) and UBS upgrading the broader biotech sector on improving fundamentals and M&A tailwinds.

2.0213

July 10, 2026Immatics N.V. closed down nearly 3% on below-average volume, with investor focus remaining on its oncology pipeline milestones rather than near-term commercial catalysts. The pullback came as biotech broadly garnered attention — Jim Cramer flagged the sector as a market leader and healthcare rose sharply last quarter — yet Immatics, as a clinical-stage T-cell therapy company, saw little company-specific news to sustain momentum. Investors continue to watch for pipeline updates as the stock's market narrative is driven by development milestones.

-2.8112

July 10, 2026Immatics N.V. closed essentially flat, holding near the $10 level as investors keep attention on its oncology pipeline rather than commercial milestones. The broader backdrop is favorable for the stock's narrative: Jim Cramer called biotech "the hottest group in the market," predicting a wave of M&A deals amid a more permissive FDA environment, while the healthcare sector has posted back-to-back market-leading weeks with XLV up over 13% in two weeks. Clinical-stage names like Immatics may attract renewed interest as large-cap acquirers such as Eli Lilly and Gilead actively pursue late-stage oncology assets.

-0.2004

July 8, 2026Immatics N.V. closed down 2.73% amid a broad risk-off session triggered by Trump declaring the Iran MOU 'over,' sending oil prices surging more than 5% and rattling global equities. Despite the macro headwinds, the biotech sector remains a focal point for investors, with Jim Cramer recently calling biotech 'the hottest group in the market' and predicting a wave of M&A deals under a more favorable FDA regulatory environment — dynamics that could benefit clinical-stage oncology companies like Immatics, whose market story remains tied to pipeline milestones in T-cell receptor (TCR) therapies.

-2.729

July 7, 2026Immatics N.V. rose in after-hours trading, continuing its session gains amid a surging biotech backdrop. On CNBC's Mad Dash, Jim Cramer called biotech 'the hottest group in the market,' predicting a wave of M&A deals driven by a more favorable FDA regulatory environment — a narrative that is lifting clinical-stage oncology names like Immatics, whose market story centers on its TCR-T cell receptor pipeline targeting solid tumors. The healthcare sector has also been the top-performing S&P 500 sector for two consecutive weeks, with XLV surging over 5%, providing additional tailwinds for the clinical-stage company.

2.7027

July 2, 2026Immatics N.V. closed modestly higher, gaining about 1% as the broader biotech sector showed resilience, with the Virtus Biotech Clinical Trials ETF recently hitting a 52-week high and investor sentiment in the space remaining constructive. The healthcare sector also got a lift from softer-than-expected U.S. jobs data, which eased Fed rate-hike concerns. No company-specific catalysts were identified for Immatics today, leaving the move largely tied to sector tailwinds and the company's ongoing clinical narrative in TCR-T cell therapy.

1.0152

July 1, 2026Immatics N.V. shares declined amid a broader biotech sector pullback, as the Nasdaq dipped and tech/chip stocks weighed on markets to start the new month and quarter. With no company-specific catalysts in focus, IMTX tracked sector weakness; the biotech space has broadly held up well in 2026 on strong clinical updates and drug approvals, but broader macro uncertainty—including softer private payrolls data and Fed Chair Warsh's remarks on inflation—dampened risk appetite for pre-revenue clinical-stage names.

-2.7641

June 26, 2026Immatics closed essentially unchanged as broader biotech sentiment remained mixed amid a volatile week for equities. Analyst consensus remains constructive, with 12 analysts rating the stock a buy and an average price target of ~$18.52—implying roughly 87% upside from current levels—though the company's most recent quarterly revenue declined 57% year-over-year, weighing on near-term sentiment. The broader healthcare sector found support from M&A tailwinds, including Merck KGaA's $11.3B acquisition of Bio-Techne, while biotech ETFs have held up well in 1H 2026 despite macro volatility.

-0.1049

Stock Titan · July 17, 2026Immatics’ three ESMO presentations span melanoma and solid tumorsQuiver Quantitative · July 17, 2026Immatics Announces Three ESMO 2026 Presentations Highlighting PRAME Cell Therapy and Bispecific PipelineInvesting News Network · July 17, 2026Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026GlobeNewswire · July 17, 2026Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026Moomoo · June 17, 2026TD Cowen Maintains Immatics(IMTX.US) With Buy RatingSeeking Alpha · June 16, 2026Immatics: PRAME Is Becoming More Than A Single-Asset Story (NASDAQ:IMTX)GlobeNewswire · May 12, 2026Immatics Announces First Quarter 2026 Financial Results and Business UpdateInvesting.com · May 12, 2026Immatics NV earnings missed by €0.04, revenue fell short of estimates
Benzinga · June 1, 2026Immatics Announces Extended Data From Phaseb Clinicla Trial Evaluating Anzu-Cel PRAME TCR T-Cell Therapy In Heavily Pretreated Patients With Advanced Melanoma At ASCO Annual Meeting
Mt Newswire · May 12, 2026Immatics Q1 Loss Widens, Revenue Falls
Benzinga · May 12, 2026Immatics Q1 EPS $(0.50) Misses $(0.42) Estimate, Sales $8.914M Miss $14.590M Estimate
Mt Newswire · May 12, 2026Earnings Flash (IMTX) Immatics Posts Q1 Revenue 7.6M Euros, vs. FactSet Est of 8.5M Euros
Mt Newswire · May 12, 2026Earnings Flash (IMTX) Immatics Posts Q1 Net Loss 0.43 Euro a Share, vs. FactSet Est of 0.45 Euro Loss
Benzinga · April 28, 2026TD Cowen Initiates Coverage On Immatics with Buy Rating
Mt Newswire · April 28, 2026TD Cowen Initiates Immatics at Buy
Benzinga · April 17, 2026Immatics Announces Its Abstract Regarding Pediatric Participant Treatment With PRAME-Directed Cell Therapy Using Its PRAME T-Cell Receptor Accpected For Poster Presentation At American Association For Cancer Research Annual Meeting 2026

Peers

S&P 500SPX · $7,457.69-1.01%Dianthus Therapeutics, Inc.DNTH · $105.60+10.75%Oruka Therapeutics, Inc.ORKA · $92.70+11.63%Kiniksa Pharmaceuticals International, plcKNSA · $63.95+4.65%ProKidney Corp.PROK · $1.62+0.62%AnaptysBio, Inc.ANAB · $58.00+7.11%uniQure N.V.QURE · $40.25+2.26%ArriVent BioPharma, Inc.AVBP · $33.19+1.31%UroGen Pharma Ltd.URGN · $40.23+0.56%Precigen, Inc.PGEN · $4.950.00%Xencor, Inc.XNCR · $17.47+16.86%Generate Biomedicines, Inc.GENB · $13.56-0.73%